Skip to main content

Adaptimmune Therapeutics PLC

ADAPY
Exchange
OTC
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001621227

No open-market purchases or sales by Adaptimmune Therapeutics PLC insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Adaptimmune Therapeutics PLC changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of ADAPY: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders6555−10
Shares115.6M42.1M−73.5M (−63.6%)
Value$27.7M$5.47M−$22.2M (−80.3%)

New holders (14)

Institutions that held Adaptimmune Therapeutics PLC at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to ADAPY in Q3 2025
InstitutionSharesValue% of portfolio
Jane Street Group, LLC2,805,345$364.7K0.00%
National Asset Management, Inc.500,000$65.0K0.00%
Lumbard & Kellner, LLC114,264$14.9K0.01%
Lakeridge Wealth Management LLC110,400$14.4K0.01%
Group One Trading, L.P.61,730$8.03K0.00%
SG Americas Securities, LLC27,497$4.00K0.00%
StoneX Group Inc.15,040$1.96K0.00%
Traynor Capital Management, Inc.15,000$1.95K0.00%
Goldman Sachs Group Inc12,320$1.60K0.00%
Rockefeller Capital Management L.P.12,166$1.58K0.00%
Simplex Trading, LLC12,424$1.00K0.00%
Citigroup Inc2,679$3480.00%
Advisory Services Network, LLC125$160.00%
EverSource Wealth Advisors, LLC100$130.00%

Sold out (24)

Institutions that held Adaptimmune Therapeutics PLC at the end of Q2 2025 and filed for Q3 2025 without it.